Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Biogen is tapping some top pharma talent to lead its medical efforts. Daniel Quirk, M.D., is the biotech’s new chief medical officer and head of medical affairs. Quirk formerly served as a senior vice ...